MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.3 USD | -4.39% |
|
-6.59% | +17.96% |
| May. 10 | Equities Mostly Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
| May. 10 | S&P 500, Dow Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.96% | 47.02B | |
| +48.77% | 41.86B | |
| +1.17% | 41.76B | |
| -4.27% | 28.8B | |
| +11.42% | 26.05B | |
| -21.39% | 19.15B | |
| +4.86% | 12.55B | |
| +27.29% | 12.34B | |
| -3.50% | 11.82B | |
| +20.18% | 11.8B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna : Confirms 93% Vaccine Efficacy Six Months After Second Dose